Conditioned taste aversions as a behavioral baseline for drug discrimination learning: an assessment with phencyclidine

Pharmacology, Biochemistry, and Behavior
J P MastropaoloAnthony L Riley

Abstract

When PCP was given prior to the pairing of saccharin with LiCl (and the PCP vehicle prior to a nonpoisoned exposure to the same saccharin solution), rats rapidly acquired the discrimination, avoiding saccharin consumption following PCP and consuming saccharin following the vehicle after only three conditioning trials. Conversely, when the PCP vehicle was given prior to the saccharin-LiCl pairing and PCP prior to a nonpoisoned exposure to saccharin, other subjects avoided saccharin consumption following the vehicle injection and readily consumed saccharin after an injection of PCP. During dose substitution sessions, animals displayed greater drug-appropriate responding as the dose of PCP increased. When a range of doses of ketamine was given in place of PCP prior to saccharin access, subjects displayed dose-dependent PCP-appropriate responding. When a range of doses of d-amphetamine was substituted for PCP, subjects displayed vehicle-appropriate responding at all doses. The relative efficacy of the taste aversion procedure as a baseline for drug discrimination learning is discussed.

References

Apr 30, 1975·Psychopharmacologia·Torbjörn U C JärbeB G Henriksson
Jun 1, 1977·Pharmacology, Biochemistry, and Behavior·D van der Kooy, A G Phillips
Mar 1, 1975·Pharmacology, Biochemistry, and Behavior·A E LeBlanc, H Cappell
Jan 1, 1985·Annals of the New York Academy of Sciences·Anthony L Riley, D L Tuck
Jan 1, 1985·Annals of the New York Academy of Sciences·I L Bernstein
May 1, 1987·Pharmacology, Biochemistry, and Behavior·J A Romano, J M King
Jan 1, 1986·Neuroscience and Biobehavioral Reviews·D A OvertonD A Merkle
Jan 1, 1985·Annals of the New York Academy of Sciences·C R Gustavson, J C Gustavson
Jan 1, 1985·Annals of the New York Academy of Sciences·P E Nathan
Jan 1, 1985·Annals of the New York Academy of Sciences·Anthony L Riley, D L Tuck
Sep 1, 1974·Pharmacology, Biochemistry, and Behavior·L Parker, B L Radow
Feb 1, 1973·Journal of Comparative and Physiological Psychology·L ParkerK Weidman
Nov 1, 1971·Psychological Review·P Rozin, J W Kalat
Apr 1, 1982·Journal of Comparative and Physiological Psychology·S RevuskyR W Pohl
Jan 1, 1983·Psychopharmacology·J M White, S G Holtzman
Feb 1, 1984·Pharmacology, Biochemistry, and Behavior·D A ZellnerAnthony L Riley
Jan 1, 1982·Annals of the New York Academy of Sciences·S G Holtzman
Feb 19, 1982·European Journal of Pharmacology·F C Colpaert, P A Janssen
Aug 1, 1982·Pharmacology, Biochemistry, and Behavior·K T Brady, R L Balster
Jan 1, 1982·Addictive Behaviors·T B Baker, D S Cannon
May 1, 1980·Pharmacology, Biochemistry, and Behavior·J Le MagnenD Miceli
Jan 7, 1978·Journal of Allied Health·R H Boatman

Citations

Aug 8, 1996·European Journal of Pharmacology·J H MaesJ M Vossen
Aug 1, 1991·Pharmacology, Biochemistry, and Behavior·F Woudenberg, T H Hijzen
Jan 1, 1992·Pharmacology, Biochemistry, and Behavior·S T SmurthwaiteAnthony L Riley
Jan 1, 1992·Pharmacology, Biochemistry, and Behavior·Glenn W StevensonAnthony L Riley
Jul 1, 1992·Pharmacology, Biochemistry, and Behavior·A Van HestB Olivier
Nov 1, 1992·Pharmacology, Biochemistry, and Behavior·S T Smurthwaite, Anthony L Riley
Sep 1, 1993·Pharmacology, Biochemistry, and Behavior·P M Melton, Anthony L Riley
Feb 1, 1993·Pharmacology, Biochemistry, and Behavior·P M MeltonAnthony L Riley
Nov 1, 1993·Pharmacology, Biochemistry, and Behavior·S Pournaghash, Anthony L Riley
Aug 1, 1994·Pharmacology, Biochemistry, and Behavior·D J MoklerL Stambaugh
Dec 1, 1994·Pharmacology, Biochemistry, and Behavior·B K ParkerM Miller
Jul 1, 1994·Pharmacology, Biochemistry, and Behavior·S T Smurthwaite, Anthony L Riley
May 1, 1994·Pharmacology, Biochemistry, and Behavior·P M Melton, Anthony L Riley
Jan 1, 1994·Neuroscience and Biobehavioral Reviews·I LuckiD S Kreiss
Nov 1, 1992·Behavioral and Neural Biology·D M Skinner, G M Martin
Jan 1, 1990·Journal of Neuroscience Methods·D A Mathis, M W Emmett-Oglesby
May 1, 1996·Progress in Neuro-psychopharmacology & Biological Psychiatry·B M Rabin
Sep 25, 1998·Physiology & Behavior·G A MickleyB K Yamamoto
Feb 13, 2001·Pharmacology, Biochemistry, and Behavior·G A MickleyR Peluso
Apr 28, 2001·Pharmacology, Biochemistry, and Behavior·F MirandaD N Velázquez-Martínez
Jun 23, 2001·Pharmacology, Biochemistry, and Behavior·M A FoxAnthony L Riley
Jan 29, 2002·Pharmacology, Biochemistry, and Behavior·Glenn W StevensonAntony L Riley
Jan 4, 1998·Pharmacology, Biochemistry, and Behavior·R V McDonaldS Siegel
Jul 27, 1999·Pharmacology, Biochemistry, and Behavior·S D GrabusAnthony L Riley
Dec 14, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Matthew I PalmatierRick A Bevins
Nov 1, 1995·Journal of Learning Disabilities·S F ShawL C Brinckerhoff
Sep 1, 1991·Journal of the Experimental Analysis of Behavior·J R GlowaAnthony L Riley
Feb 7, 2020·Current Pharmaceutical Design·Matthew M ClasenTerry L Davidson

Related Concepts

Metazoa
Avoidance Learning
Conditioned Reflex
Oxydess
Discrimination Learning
Ketaset
Phencyclidine Hydrobromide
August Rats
Taste Perception
Rats, Laboratory

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Systemic Juvenile Idiopathic Arthritis

Systemic juvenile idiopathic arthritis is a rare rheumatic disease that affects children. Symptoms include joint pain, but also fevers and skin rashes. Here is the latest on this disease.

Chromatin Regulation and Circadian Clocks

The circadian clock plays an important role in regulating transcriptional dynamics through changes in chromatin folding and remodelling. Discover the latest research on Chromatin Regulation and Circadian Clocks here.

Central Pontine Myelinolysis

Central Pontine Myelinolysis is a neurologic disorder caused most frequently by rapid correction of hyponatremia and is characterized by demyelination that affects the central portion of the base of the pons. Here is the latest research on this disease.

Myocardial Stunning

Myocardial stunning is a mechanical dysfunction that persists after reperfusion of previously ischemic tissue in the absence of irreversible damage including myocardial necrosis. Here is the latest research.

Pontocerebellar Hypoplasia

Pontocerebellar hypoplasias are a group of neurodegenerative autosomal recessive disorders with prenatal onset, atrophy or hypoplasia of the cerebellum, hypoplasia of the ventral pons, microcephaly, variable neocortical atrophy and severe mental and motor impairments. Here is the latest research on pontocerebellar hypoplasia.

Cell Atlas Along the Gut-Brain Axis

Profiling cells along the gut-brain axis at the single cell level will provide unique information for each cell type, a three-dimensional map of how cell types work together to form tissues, and insights into how changes in the map underlie health and disease of the GI system and its crosstalk with the brain. Disocver the latest research on single cell analysis of the gut-brain axis here.

Chronic Traumatic Encephalopathy

Chronic Traumatic Encephalopathy (CTE) is a progressive degenerative disease that occurs in individuals that suffer repetitive brain trauma. Discover the latest research on traumatic encephalopathy here.